Changes in cytokine production of breast cancer patients treated with interferons

Vivian Barak*, Inna Kalickman, Benjamin Nisman, Hanan Farbstein, Zvi G. Fridlender, Lea Baider, Atara Kaplan, Samir Stephanos, Tamar Peretz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


A clinical randomized study was performed on advanced breast cancer patients which were treated by interferons (IFN) β and γ in combination with hormonotherapy (Megace or Tamoxifen). Cytokine levels (IL-1β, IL-2, IL-6, TNF-α, IFN-γ) and sIL-2R of individual patients before, during (3 months) and after (6 months) therapy were evaluated and correlated to clinical response according to UICC criteria (responder patients - Partial or Complete Response versus non-responder patients - Stable/Progression). Decreases in IL-1β, IL-6 and sIL-2R were associated with clinical response to therapy versus increases in their levels which corresponded to progression of disease. A significant and dramatic increase in IFN-γ levels was associated with a favourable response to therapy in the IFNs-treated patients, mainly in the group of Tamoxifen. Baseline levels of sIL-2R and of IFN-γ were prognostic of clinical response and were found to be the most sensitive cytokine parameters for defining the clinical utility of the combination of IFNs and hormonotherapy in breast cancer patients.

Original languageAmerican English
Pages (from-to)977-983
Number of pages7
Issue number12
StatePublished - Dec 1998
Externally publishedYes


  • Breast cancer
  • Cytokine receptors
  • Cytokines
  • Interferons


Dive into the research topics of 'Changes in cytokine production of breast cancer patients treated with interferons'. Together they form a unique fingerprint.

Cite this